Long-term Efficacy of Satralizumab in AQP4-IgG–Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar

BACKGROUND AND OBJECTIVES: Satralizumab, an interleukin 6 receptor inhibitor, reduced the risk of protocol-defined relapse (PDR) vs placebo in 2 independent, double-blind studies in patients with neuromyelitis optica spectrum disorder (NMOSD). We assessed the long-term efficacy of satralizumab in pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleiter, Ingo, Traboulsee, Anthony, Palace, Jacqueline, Yamamura, Takashi, Fujihara, Kazuo, Saiz, Albert, Javed, Adil, Mayes, David, von Büdingen, H-Christian, Klingelschmitt, Gaelle, Stokmaier, Daniela, Bennett, Jeffrey L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756307/
https://www.ncbi.nlm.nih.gov/pubmed/36724181
http://dx.doi.org/10.1212/NXI.0000000000200071

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756307/
https://www.ncbi.nlm.nih.gov/pubmed/36724181
http://dx.doi.org/10.1212/NXI.0000000000200071

Ejemplares similares